Glowing dye could help surgeons spot hidden lung cancer spread
NCT ID NCT00264602
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tests whether a dye called indocyanine green, injected near a lung tumor during surgery, can help surgeons see and remove the first lymph node that drains from the cancer. The goal is to improve detection of cancer spread and guide more precise treatment. The trial involves 57 adults with operable lung cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Indocyanine Green (a dye) injected near the tumor during surgery
What this could lead to
If successful, this technique could help surgeons more accurately identify and remove the lymph node most likely to contain cancer cells, potentially improving staging and treatment decisions for lung cancer patients.
What could go wrong
This is a very early (Phase 1) trial with only 57 participants, so results may not apply to all lung cancer patients. The dye or imaging might not reliably find the correct lymph node, and the procedure carries standard surgical risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States